My Mindful Moments: A Mindfulness Meditation and Digital Art Activity

The purpose of this evidence-based practice project is to evaluate the feasibility of providing a relaxation mindfulness meditation and an expressive digital arts activity among clinical staff at Dana Farber Cancer Institute .

Study Overview

• Status: Completed
• Conditions: Meditation; Mindfulness
• Intervention / Treatment: Other: Mindfulness intervention

Detailed Description

This project provides an opportunity for patient care staff in an ambulatory oncology setting to participate in and evaluate an activity that includes a mindfulness meditation technique and an expressive digital arts activity.

This study will be conducted to evaluate the feasibility of providing a mindfulness meditation and digital imagery activity.

• The activity will include a guided mindfulness meditation and the creation of a digital image on an iPad.
• Participants will be asked to complete brief surveys before and after the intervention activity.

• Study Type: Interventional
• Enrollment (Actual): 16
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Massachusetts
    • Boston, Massachusetts, United States, 02215
      • Dana Farber Cancer Institute

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Adults ≥18 years of age
• Currently employed at Dana Farber Cancer Institute
• Providing patient care on Yawkey

Exclusion Criteria:

• Not an employee of Dana Farber Cancer Institute
• Not providing Patient Care on Yawkey

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Supportive Care
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Mindful Meditation; The activity will include a guided mindfulness meditation and the creation of a digital image on an iPad.; The My Moments® application (app) is a tool used to facilitate expressive art creation in a digital photography media; Participants will be asked to complete brief surveys before and after the intervention activity.	Other: Mindfulness intervention; My Moments® application (app) is a tool used to facilitate expressive art creation in a digital photography media

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participation-Feasibility	≥50% of staff choose to participate=Feasibility. This measure of feasibility will be evaluated by calculating index scores of the percentage of clinical staff who choose to participate	1 year
Percentage Completion of Full Activity-Feasibility	> 80% of those who participate complete the activity=Feasibility. This measure of feasibility will be evaluated by index scores of the percentage of clinical staff who complete the full activity	1 year
Mean Completion Time-Feasibility	The activity is completed by the group in 40 minutes or less-Feasibility. This measure of feasibility will be evaluatedby individual group completions times and overall analysis of descriptive statistics on the time for completion of the activity by all groups.	1 year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Anxiety Score	Changes in participant state anxiety will be evaluated using the visual analogue scale in measuring state anxiety. The electronic scale displays a horizontal line divided into 30 equal-sized partitions. The left edge of the scale is marked "calm" and the right edge is marked "anxious." A sliding locator is positioned at the midpoint of the scale. The participant is instructed to use the computer mouse to place the locator at the scale position representing their current level of anxiety. The score is automatically calculated by rounding the relative distance of the locator from the left edge of the scale to the nearest integer value between 0 and 30. A higher score indicates greater anxiety. A comparison of scores pre- and post- intervention by calculating a paired t-test comparison of means	1 Year

Collaborators and Investigators

• Sponsor: Dana-Farber Cancer Institute
• Investigators: Principal Investigator: Terri Jabaley, Ph.D, RN, Dana-Farber Cancer Institute

Study record dates

Study Major Dates

• Study Start (Actual): July 1, 2021
• Primary Completion (Actual): July 30, 2022
• Study Completion (Actual): July 30, 2022

Study Registration Dates

• First Submitted: September 15, 2020
• First Submitted That Met QC Criteria: September 15, 2020
• First Posted (Actual): September 21, 2020

Study Record Updates

• Last Update Posted (Actual): August 25, 2022
• Last Update Submitted That Met QC Criteria: August 22, 2022
• Last Verified: August 1, 2022

More Information

Terms related to this study

• Keywords: Mindfulness; Meditation
• Other Study ID Numbers: 20-420

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to Sponsor Investigator or designee. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
• IPD Sharing Time Frame: Data can be shared no earlier than 1 year following the date of publication
• IPD Sharing Access Criteria: DFCI - Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ICF

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No